Adam Belley
About
Adam Belley is a scholar working on Pharmacology, Infectious Diseases and Molecular Medicine.
According to data from OpenAlex, Adam Belley has authored 32 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pharmacology, 17 papers in Infectious Diseases and 15 papers in Molecular Medicine. Recurrent topics in Adam Belley's work include Antibiotics Pharmacokinetics and Efficacy (23 papers), Antimicrobial Resistance in Staphylococcus (17 papers) and Antibiotic Resistance in Bacteria (15 papers). Adam Belley is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (23 papers), Antimicrobial Resistance in Staphylococcus (17 papers) and Antibiotic Resistance in Bacteria (15 papers). Adam Belley collaborates with scholars based in United States, Canada and United Kingdom. Adam Belley's co-authors include Greg Moeck, Francis F. Arhin, Geoffrey A. McKay, Thomas Parr, Ingrid Sarmiento, Sylvain Beaulieu, Terry J. Beveridge, Philipp Knechtle, Daniel F. Sahm and Deborah C. Draghi and has published in prestigious journals such as JAMA, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.
In The Last Decade
Adam Belley
29 papers receiving 872 citations
Peers
Adam Belley
Céline Vidaillac United States
Razieh Kebriaei United States
Linda A. Bester South Africa
Klaudia Kosowska-Shick United States
Chris M. Pillar United States
Gengrong Lin United States
Deborah Ashcraft United States
Javier Fernández Spain
Lois M. Ednie United States
Jane E. Ambler United States
Citations per year, relative to Adam Belley Adam Belley (= 1×)
peers
Céline Vidaillac
Countries citing papers authored by Adam Belley
Since
Specialization
Citations
This map shows the geographic impact of Adam Belley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Belley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Belley more than expected).
Fields of papers citing papers by Adam Belley
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Adam Belley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Belley. The network helps show where Adam Belley may publish in the future.
Co-authorship network of co-authors of Adam Belley
This figure shows the co-authorship network connecting the top 25 collaborators of Adam Belley. A scholar is included among the top collaborators of Adam Belley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Belley. Adam Belley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Belley, Adam, et al.. (2025). Establishing the reference broth microdilution MIC method for cefepime-taniborbactam. Journal of Clinical Microbiology. 63(9). e0066125–e0066125.
2.
Morrissey, Ian, Stephen Hawser, N. Dunkel, et al.. (2024). Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates. Journal of Global Antimicrobial Resistance. 38. 71–82.
3.
Belley, Adam, et al.. (2023). Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae. The Journal of Antibiotics. 76(3). 183–189.
4.
Belley, Adam, et al.. (2023). 1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021. Open Forum Infectious Diseases. 10(Supplement_2).
5.
Kaye, Keith S., et al.. (2022). Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis. JAMA. 328(13). 1304–1304.
6.
Belley, Adam, et al.. (2021). Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam. Journal of Global Antimicrobial Resistance. 25. 93–101.
7.
Johnson, Adam, Laura McEntee, Nicola Farrington, et al.. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 64(6).
8.
Belley, Adam, et al.. (2020). LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales. Open Forum Infectious Diseases. 7(Supplement_1). S845–S845.
9.
Belley, Adam, Michael D. Huband, Amy A. Watters, et al.. (2019). Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam. Journal of Clinical Microbiology. 57(8).
10.
Belley, Adam, et al.. (2017). Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection. Antimicrobial Agents and Chemotherapy. 61(10).
11.
Arhin, Francis F., David Lalonde Séguin, Adam Belley, & Greg Moeck. (2017). In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagnostic Microbiology and Infectious Disease. 89(2). 168–171.
12.
Shinabarger, Dean L., et al.. (2016). Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease. 87(2). 121–128.
13.
Belley, Adam, Geoffrey A. McKay, Francis F. Arhin, et al.. (2010). Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing. Antimicrobial Agents and Chemotherapy. 54(12). 5369–5371.
14.
Arhin, Francis F., Adam Belley, Geoffrey A. McKay, et al.. (2010). Assessment of Oritavancin Serum Protein Binding across Species. Antimicrobial Agents and Chemotherapy. 54(8). 3481–3483.
15.
McKay, Geoffrey A., Sylvain Beaulieu, Francis F. Arhin, et al.. (2009). Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. Journal of Antimicrobial Chemotherapy. 63(6). 1191–1199.
16.
Belley, Adam, et al.. (2008). Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 52(10). 3820–3822.
17.
Belley, Adam, et al.. (2008). Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Antimicrobial Agents and Chemotherapy. 53(2). 800–804.
18.
Ciblat, Stéphane, Adam Belley, Evelyne Dietrich, et al.. (2006). Novel Non‐Nucleobase Inhibitors of Staphylococcus aureus DNA Polymerase IIIC.. ChemInform. 37(17).
19.
Ciblat, Stéphane, Adam Belley, Evelyne Dietrich, et al.. (2005). Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC. Bioorganic & Medicinal Chemistry Letters. 16(4). 891–896.
20.
McKay, Geoffrey A., Francis F. Arhin, Adam Belley, et al.. (2005). Triaminotriazine DNA helicase inhibitors with antibacterial activity. Bioorganic & Medicinal Chemistry Letters. 16(5). 1286–1290.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Céline Vidaillac Breakdown of academic impact, for papers by Razieh Kebriaei Breakdown of academic impact, for papers by Linda A. Bester Breakdown of academic impact, for papers by Klaudia Kosowska-Shick Breakdown of academic impact, for papers by Chris M. Pillar Breakdown of academic impact, for papers by Gengrong Lin Breakdown of academic impact, for papers by Deborah Ashcraft Breakdown of academic impact, for papers by Javier Fernández Breakdown of academic impact, for papers by Lois M. Ednie Breakdown of academic impact, for papers by Jane E. Ambler